Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M39,782Revenue $M10,235Net Margin (%)14.5Z-Score3.3
Enterprise Value $M43,625EPS $3.6Operating Margin %18.6F-Score6
P/E(ttm))25.3Cash Flow Per Share $5.3Pre-tax Margin (%)17.8Higher ROA y-yN
Price/Book4.210-y EBITDA Growth Rate %7.1Quick Ratio1.5Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %7.2Current Ratio2.0Lower Leverage y-yN
Price/Cash Flow11.0y-y EBITDA Growth Rate %2.1ROA % (ttm)7.6Higher Current Ratio y-yN
Dividend Yield %1.4Insider Buy (3m)2ROE % (ttm)15.9Less Shares Outstanding y-yY
Payout Ratio %37.0Shares Outstanding M451ROI % (ttm)10.6Gross Margin Increase y-yY

Gurus Latest Trades with COV

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
COVJohn Paulson 2014-06-30 Buy 2.7%$69.03 - $91.24
($74.56)
$ 88.0618%New holding, 7000000 sh.7,000,000
COVGeorge Soros 2014-06-30 Buy 0.15%$69.03 - $91.24
($74.56)
$ 88.0618%New holding, 227000 sh.227,000
COVJoel Greenblatt 2014-06-30 Sold Out $69.03 - $91.24
($74.56)
$ 88.0618%Sold Out0
COVYacktman Focused Fund 2014-06-30 Sold Out -0.62%$69.03 - $91.24
($74.56)
$ 88.0618%Sold Out0
COVYacktman Fund 2014-06-30 Sold Out -0.56%$69.03 - $91.24
($74.56)
$ 88.0618%Sold Out0
COVDonald Yacktman 2014-06-30 Sold Out -0.55%$69.03 - $91.24
($74.56)
$ 88.0618%Sold Out0
COVRay Dalio 2014-06-30 Sold Out -0.03%$69.03 - $91.24
($74.56)
$ 88.0618%Sold Out0
COVJoel Greenblatt 2014-03-31 Buy $66.35 - $72.5
($69.62)
$ 88.0626%New holding, 3746 sh.3,746
COVRay Dalio 2014-03-31 Reduce-0.02%$66.35 - $72.5
($69.62)
$ 88.0626%Reduce -41.8%47,058
COVVanguard Health Care Fund 2013-12-31 Add0.22%$59.82 - $68.42
($65.08)
$ 88.0635%Add 24.79%4,994,700
COVRay Dalio 2013-12-31 Buy 0.04%$59.82 - $68.42
($65.08)
$ 88.0635%New holding, 80858 sh.80,858
COVJohn Keeley 2013-12-31 Reduce-0.06%$59.82 - $68.42
($65.08)
$ 88.0635%Reduce -52.66%44,520
COVJoel Greenblatt 2013-12-31 Sold Out -0.03%$59.82 - $68.42
($65.08)
$ 88.0635%Sold Out0
COVJoel Greenblatt 2013-09-30 Reduce-0.08%$57.12 - $63.8
($61.08)
$ 88.0644%Reduce -64.08%16,584
COVVanguard Health Care Fund 2013-06-30 Add0.37%$50.69 - $56.84
($54.09)
$ 88.0663%Add 66.94%4,002,600
COVJoel Greenblatt 2013-06-30 Buy 0.12%$50.69 - $56.84
($54.09)
$ 88.0663%New holding, 46170 sh.46,170
COVRonald Muhlenkamp 2013-06-30 Reduce-2.78%$50.69 - $56.84
($54.09)
$ 88.0663%Reduce -53.5%174,170
COVJean-Marie Eveillard 2013-06-30 Reduce-0.16%$50.69 - $56.84
($54.09)
$ 88.0663%Reduce -99.79%1,500
COVLeon Cooperman 2013-06-30 Sold Out -0.04%$50.69 - $56.84
($54.09)
$ 88.0663%Sold Out0
COVRay Dalio 2013-06-30 Sold Out -0.04%$50.69 - $56.84
($54.09)
$ 88.0663%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

COV is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
COV George Soros 2014-06-30227,0000.050.15New Buy
COV John Paulson 2014-06-307,000,0001.552.7New Buy
COV Mario Gabelli 2014-06-30637,5300.140.3+17.29%
COV Ronald Muhlenkamp 2014-06-30182,1800.042.9+0.4%
COV Jean-Marie Eveillard 2014-06-301,50000
COV Vanguard Health Care Fund 2014-06-304,994,7001.111.2
COV John Keeley 2014-06-3040,8400.010.07-6.69%
COV Dodge & Cox 2014-06-3092,0170.020.01-9.36%
COV Donald Yacktman 2014-06-30000Sold Out
COV Ray Dalio 2014-06-30000Sold Out
COV Joel Greenblatt 2014-06-30000Sold Out
COV Yacktman Fund 2014-06-30000Sold Out
COV Yacktman Focused Fund 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


COV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lannum Coleman N IIIVice President 2014-08-27Buy3,338$87.234.15view
Lannum Coleman N IIIVice President 2014-08-26Buy1,736$87.463.88view
Lannum Coleman N IIIVice President 2014-08-19Buy1,720$87.823.45view
Lannum Coleman N IIIVice President 2014-08-18Buy4,100$87.583.73view
BROWN RICHARD G JRVice President and Controller 2014-08-18Buy2,000$87.693.6view
ALMEIDA JOSE EPresident and Chief Executive 2014-06-16Sell51,166$92.05-1.3view
King Brian DouglasVice President 2014-04-29Sell15,569$70.1129.58view
Dockendorff Charles JEVP & CFO 2014-03-28Sell90,730$72.525.31view
ALMEIDA JOSE EPresident and Chief Executive 2014-02-28Sell50,000$7226.18view
Lannum Coleman N IIIVice President 2014-02-18Sell3,200$71.427.24view

Press Releases about COV :

Quarterly/Annual Reports about COV:

News about COV:

Articles On GuruFocus.com
Gabelli Value 25 Fund Second Quarter Commentary Sep 15 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
Abbott: A Brighter Future Aug 28 2014 
A Strong Candidate for Investor´s Portfolios Aug 12 2014 
The Gabelli Equity Income Fund Second Quarter 2014 Shareholder Commentary Jul 25 2014 
Steven Romick's Top Five Stocks Jul 11 2014 
American Water Works - Nice Steady Upward Jun 21 2014 
Major British Companies Lead Top Guru-Held UK and Ireland Stocks Jun 10 2014 
4 Top Stocks in the Medical Device Sector Apr 11 2014 
Weekly Insider Sells Highlight: CUK, CBI, COV, DWRE Mar 30 2014 


More From Other Websites
Covidien Sonicision Line Expands, 3 Devices Gain FDA Nod Sep 19 2014
Why Covidien (COV) Stock Rose Today Sep 18 2014
Covidien Announces Double-Digit Dividend Rise for 6th Year Sep 18 2014
Capitalize On Wall Street's Latest Tax Craze Sep 18 2014
Covidien SonicisionTM Portfolio Expansion Enables Surgeons to Choose Ideal Cordless Ultrasonic... Sep 18 2014
Covidien Announces Dividend Increase Sep 17 2014
Covidien's Two Neurovascular Trial Enrolments on Track Sep 16 2014
Covidien Announces Start of Enrollment in Two Neurovascular Clinical Trials Sep 15 2014
Covidien Announces Start of Enrollment in Two Neurovascular Clinical Trials Sep 15 2014
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014
[video] Inversion crackdown all talk, no action? Sep 08 2014
The Zacks Analyst Blog Highlights: EGShares India Small Cap ETF, VanEck India Small Cap Index ETF,... Sep 08 2014
With Actively Managed Funds, Be Wary Of Expense Ratios Sep 04 2014
Paulson & Co. establishes a new position in Covidien in Q2 2014 Sep 04 2014
The Zacks Analyst Blog Highlights: Medtronic, Covidien, Bacterin International Holdings, Inogen and... Sep 03 2014
Solution Designed Specifically for Med/Surg Floors Addresses Unmet Patient Surveillance Needs,... Sep 01 2014
Covidien Acquires Venous Disease Cure Developer Aug 29 2014
Covidien Acquires Venous Disease Treatment Developer Sapheon, Inc. Aug 28 2014
Mallinckrodt Nears Buy Point As Sales, Earnings Rise Aug 27 2014
Zacks Industry Outlook Highlights: Zimmer Holdings, Medtronic, Covidien, Stryker and Smith & Nephew Aug 27 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK